FDA Takes Step to Reduce Smoking Rates, Proposes Lowering Nicotine Levels in Cigarettes
The FDA has issued an advance notice of proposed rulemaking in a move to lower nicotine in combustible cigarettes to minimal or non-addictive levels.
As part of the FDA’s comprehensive plan on tobacco and nicotine regulation, FDA Commissioner Scott Gottlieb, MD, has
“We're at a crossroads when it comes to addressing nicotine addiction and smoking in this country—with important new tools to address this devastating public health burden,” he said in the statement.
With years of aggressive efforts put in place to tackle tobacco use, particularly cigarette smoking, rates of cigarette smoking among US adults have declined over the last decade, falling from 24.7% in 1997 to 14.1% in January to September 2017, according to a new
With the advance notice of proposed rulemaking, the FDA is asking the public to weigh in on critical questions, including: what potential maximum nicotine level would be appropriate for the protection of public health? Should a product standard be implemented all at once or gradually? What unintended consequences, such as the potential for illicit trade or for addicted smokers to compensate for lower nicotine by smoking more, might occur as a result?
A study published in the
According to the analysis, with the implementation of the policy, 5 million additional adult smokers would quit smoking a year after the implementation, and that number would increase to a total of 13 million additional adult smokers quitting within 5 years. By 2100, the number of former smokers would increase to 33.1 million.
Looking at the number of tobacco-related deaths avoided and life-years gained because of the policy, the researchers determined that by 2060, an estimated 2.8 million tobacco-related deaths would be prevented; that number would rise to 8.5 million by 2100. The decline in deaths would result in 33.1 million life-years gained by 2060 and 134.4 million gained by 2100.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025